How to appeal a Blue Cross Blue Shield of Michigan atopic dermatitis (ad / eczema) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Michigan-specific note: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.

What Blue Cross Blue Shield of Michigan's policy requires for atopic dermatitis (ad / eczema)

Cited policy: BCBS Ebglyss (Lebrikizumab) for AD PA

Age >=12 yr and >=40 kg per Sep 2024 label. Moderate-severe AD. Failure of topical therapy. Step-therapy through Dupixent typical; contraindication or AE accepted. Reauth 16 wk EASI-75 or IGA 0/1.

How Blue Cross Blue Shield of Michigan denies atopic dermatitis (ad / eczema) — and how to counter it

Where Blue Cross Blue Shield of Michigan pushes back: 1) Try Dupixent or Adbry first; 2) Insufficient evidence vs older biologics.

Counter-arguments that hold up: Ebglyss IL-13 high-affinity binding (distinct epitope from Adbry / Dupixent IL-4Rα). FDA Sep 13, 2024 ages 12+ supported by ADvocate-1 + ADvocate-2 (Silverberg NEJM 2023 — EASI-75 ~58% vs ~16% placebo at 16 wk monotherapy), ADhere (with TCS), ADore (12-17). AAD 2024 + ETFAD/EADV 2024 list IL-13 selective biologics as parallel options. Class switching after Dupixent AE (conjunctivitis, facial dermatitis) or partial response is rational.

What Blue Cross Blue Shield of Michigan typically denies for atopic dermatitis (ad / eczema)

Across Blue Cross Blue Shield of Michigan's commercial and Medicare books, denials cluster around a small number of patterns. For atopic dermatitis (ad / eczema), expect:

• Step therapy via OptumRx (PBM since 2024)
• Site-of-care reductions for infusions
• Behavioral health prior auth
• OON balance bill disputes

Treatments most often denied in this category

These are the atopic dermatitis (ad / eczema) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (AD)
• Adbry
• Ebglyss
• Nemluvio (AD)
• Cibinqo
• Rinvoq (AD)

How to submit the appeal to Blue Cross Blue Shield of Michigan

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Michigan cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Michigan's portal (members: https://www.bcbsm.com ; providers: https://providers.bcbsm.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MI, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Michigan's prior-authorization criteria by drug: Blue Cross Blue Shield of Michigan PA criteria on ApprovalHelp.